A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy
Crossref DOI link: https://doi.org/10.1007/s10549-014-3120-6
Published Online: 2014-09-27
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Buchner, Anton
Elsässer, Reiner
Bias, Peter
License valid from 2014-09-27